Jump to content
RemedySpot.com

NS5A inhibitors: a new breakthrough for the treatment of chronic hepatitis C.

Rate this topic


Recommended Posts

Posted

J Hepatol. 2010 Dec 15. [Epub ahead of print]

NS5A inhibitors: a new breakthrough for the treatment of chronic hepatitis C.

Asselah T.

Service d'hépatologie, Hôpital Beaujon, APHP, University Paris 7 Denis Diderot

and INSERM, U773, CRB3, and Clichy, France.

Abstract

The worldwide prevalence of chronic hepatitis C virus (HCV) infection is

estimated to be approaching 200 million people. Current therapy relies upon a

combination of pegylated interferon-alpha and ribavirin, a poorly tolerated

regimen typically associated with less than 50% sustained virological response

rate in those infected with genotype 1 virus. The development of direct-acting

antiviral agents to treat HCV has focused predominantly on inhibitors of the

viral enzymes NS3 protease and the RNA-dependent RNA polymerase NS5B. Here we

describe the profile of BMS-790052, a small molecule inhibitor of the HCV NS5A

protein that exhibits picomolar half-maximum effective concentrations (EC(50))

towards replicons expressing a broad range of HCV genotypes and the JFH-1

genotype 2a infectious virus in cell culture. In a phase I clinical trial in

patients chronically infected with HCV, administration of a single 100-mg dose

of BMS-790052 was associated with a 3.3 log(10) reduction in mean viral load

measured 24 h post-dose that was sustained for an additional 120 h in two

patients infected with genotype 1b virus. Genotypic analysis of samples taken at

baseline, 24 and 144 h post-dose revealed that the major HCV variants observed

had substitutions at amino-acid positions identified using the in vitro replicon

system. These results provide the first clinical validation of an inhibitor of

HCV NS5A, a protein with no known enzymatic function, as an approach to the

suppression of virus replication that offers potential as part of a therapeutic

regimen based on combinations of HCV inhibitors.

. Published by Elsevier B.V.

PMID: 21167889 [PubMed - as supplied by publisher]

Posted

J Hepatol. 2010 Dec 15. [Epub ahead of print]

NS5A inhibitors: a new breakthrough for the treatment of chronic hepatitis C.

Asselah T.

Service d'hépatologie, Hôpital Beaujon, APHP, University Paris 7 Denis Diderot

and INSERM, U773, CRB3, and Clichy, France.

Abstract

The worldwide prevalence of chronic hepatitis C virus (HCV) infection is

estimated to be approaching 200 million people. Current therapy relies upon a

combination of pegylated interferon-alpha and ribavirin, a poorly tolerated

regimen typically associated with less than 50% sustained virological response

rate in those infected with genotype 1 virus. The development of direct-acting

antiviral agents to treat HCV has focused predominantly on inhibitors of the

viral enzymes NS3 protease and the RNA-dependent RNA polymerase NS5B. Here we

describe the profile of BMS-790052, a small molecule inhibitor of the HCV NS5A

protein that exhibits picomolar half-maximum effective concentrations (EC(50))

towards replicons expressing a broad range of HCV genotypes and the JFH-1

genotype 2a infectious virus in cell culture. In a phase I clinical trial in

patients chronically infected with HCV, administration of a single 100-mg dose

of BMS-790052 was associated with a 3.3 log(10) reduction in mean viral load

measured 24 h post-dose that was sustained for an additional 120 h in two

patients infected with genotype 1b virus. Genotypic analysis of samples taken at

baseline, 24 and 144 h post-dose revealed that the major HCV variants observed

had substitutions at amino-acid positions identified using the in vitro replicon

system. These results provide the first clinical validation of an inhibitor of

HCV NS5A, a protein with no known enzymatic function, as an approach to the

suppression of virus replication that offers potential as part of a therapeutic

regimen based on combinations of HCV inhibitors.

. Published by Elsevier B.V.

PMID: 21167889 [PubMed - as supplied by publisher]

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...